239 related articles for article (PubMed ID: 28477336)
1. RAD51 as a potential surrogate marker for DNA repair capacity in solid malignancies.
Gachechiladze M; Škarda J; Soltermann A; Joerger M
Int J Cancer; 2017 Oct; 141(7):1286-1294. PubMed ID: 28477336
[TBL] [Abstract][Full Text] [Related]
2. RAD51 foci as a functional biomarker of homologous recombination repair and PARP inhibitor resistance in germline BRCA-mutated breast cancer.
Cruz C; Castroviejo-Bermejo M; Gutiérrez-Enríquez S; Llop-Guevara A; Ibrahim YH; Gris-Oliver A; Bonache S; Morancho B; Bruna A; Rueda OM; Lai Z; Polanska UM; Jones GN; Kristel P; de Bustos L; Guzman M; Rodríguez O; Grueso J; Montalban G; Caratú G; Mancuso F; Fasani R; Jiménez J; Howat WJ; Dougherty B; Vivancos A; Nuciforo P; Serres-Créixams X; Rubio IT; Oaknin A; Cadogan E; Barrett JC; Caldas C; Baselga J; Saura C; Cortés J; Arribas J; Jonkers J; Díez O; O'Connor MJ; Balmaña J; Serra V
Ann Oncol; 2018 May; 29(5):1203-1210. PubMed ID: 29635390
[TBL] [Abstract][Full Text] [Related]
3. BET proteins regulate homologous recombination-mediated DNA repair: BRCAness and implications for cancer therapy.
Mio C; Gerratana L; Bolis M; Caponnetto F; Zanello A; Barbina M; Di Loreto C; Garattini E; Damante G; Puglisi F
Int J Cancer; 2019 Feb; 144(4):755-766. PubMed ID: 30259975
[TBL] [Abstract][Full Text] [Related]
4. Acquired resistance to combination treatment with temozolomide and ABT-888 is mediated by both base excision repair and homologous recombination DNA repair pathways.
Liu X; Han EK; Anderson M; Shi Y; Semizarov D; Wang G; McGonigal T; Roberts L; Lasko L; Palma J; Zhu GD; Penning T; Rosenberg S; Giranda VL; Luo Y; Leverson J; Johnson EF; Shoemaker AR
Mol Cancer Res; 2009 Oct; 7(10):1686-92. PubMed ID: 19825992
[TBL] [Abstract][Full Text] [Related]
5. [Abnormalities of DNA repair and gynecological cancers].
Auguste A; Leary A
Bull Cancer; 2017 Nov; 104(11):971-980. PubMed ID: 29054544
[TBL] [Abstract][Full Text] [Related]
6. Suppression of Jab1/CSN5 induces radio- and chemo-sensitivity in nasopharyngeal carcinoma through changes to the DNA damage and repair pathways.
Pan Y; Zhang Q; Atsaves V; Yang H; Claret FX
Oncogene; 2013 May; 32(22):2756-66. PubMed ID: 22797071
[TBL] [Abstract][Full Text] [Related]
7. RNA-seq profiling of a radiation resistant and radiation sensitive prostate cancer cell line highlights opposing regulation of DNA repair and targets for radiosensitization.
Young A; Berry R; Holloway AF; Blackburn NB; Dickinson JL; Skala M; Phillips JL; Brettingham-Moore KH
BMC Cancer; 2014 Nov; 14():808. PubMed ID: 25369795
[TBL] [Abstract][Full Text] [Related]
8. Biomarkers of Response and Resistance to DNA Repair Targeted Therapies.
Stover EH; Konstantinopoulos PA; Matulonis UA; Swisher EM
Clin Cancer Res; 2016 Dec; 22(23):5651-5660. PubMed ID: 27678458
[TBL] [Abstract][Full Text] [Related]
9. Poly(ADP-ribose) polymerase inhibitors in cancer treatment: a clinical perspective.
Sandhu SK; Yap TA; de Bono JS
Eur J Cancer; 2010 Jan; 46(1):9-20. PubMed ID: 19926276
[TBL] [Abstract][Full Text] [Related]
10. Genetic variations in DNA repair genes, radiosensitivity to cancer and susceptibility to acute tissue reactions in radiotherapy-treated cancer patients.
Chistiakov DA; Voronova NV; Chistiakov PA
Acta Oncol; 2008; 47(5):809-24. PubMed ID: 18568480
[TBL] [Abstract][Full Text] [Related]
11. Predictive biomarkers for cancer therapy with PARP inhibitors.
Michels J; Vitale I; Saparbaev M; Castedo M; Kroemer G
Oncogene; 2014 Jul; 33(30):3894-907. PubMed ID: 24037533
[TBL] [Abstract][Full Text] [Related]
12. CircCDYL2 bolsters radiotherapy resistance in nasopharyngeal carcinoma by promoting RAD51 translation initiation for enhanced homologous recombination repair.
Qu H; Wang Y; Yan Q; Fan C; Zhang X; Wang D; Guo C; Chen P; Shi L; Liao Q; Zhou M; Wang F; Zeng Z; Xiang B; Xiong W
J Exp Clin Cancer Res; 2024 Apr; 43(1):122. PubMed ID: 38654320
[TBL] [Abstract][Full Text] [Related]
13. Targeting the DNA damage response in oncology: past, present and future perspectives.
Basu B; Yap TA; Molife LR; de Bono JS
Curr Opin Oncol; 2012 May; 24(3):316-24. PubMed ID: 22476188
[TBL] [Abstract][Full Text] [Related]
14. Natural product β-thujaplicin inhibits homologous recombination repair and sensitizes cancer cells to radiation therapy.
Zhang L; Peng Y; Uray IP; Shen J; Wang L; Peng X; Brown PH; Tu W; Peng G
DNA Repair (Amst); 2017 Dec; 60():89-101. PubMed ID: 29112893
[TBL] [Abstract][Full Text] [Related]
15. Homologous recombination and cell cycle checkpoints: Rad51 in tumour progression and therapy resistance.
Henning W; Stürzbecher HW
Toxicology; 2003 Nov; 193(1-2):91-109. PubMed ID: 14599770
[TBL] [Abstract][Full Text] [Related]
16. Effect of MRE11 loss on PARP-inhibitor sensitivity in endometrial cancer in vitro.
Koppensteiner R; Samartzis EP; Noske A; von Teichman A; Dedes I; Gwerder M; Imesch P; Ikenberg K; Moch H; Fink D; Stucki M; Dedes KJ
PLoS One; 2014; 9(6):e100041. PubMed ID: 24927325
[TBL] [Abstract][Full Text] [Related]
17. Clinical Application of Poly(ADP-Ribose) Polymerase Inhibitors in High-Grade Serous Ovarian Cancer.
Parkes EE; Kennedy RD
Oncologist; 2016 May; 21(5):586-93. PubMed ID: 27022037
[TBL] [Abstract][Full Text] [Related]
18. [DNA repair as a therapeutic target].
Eberst L; Brahmi M; Cassier PA
Bull Cancer; 2017 Nov; 104(11):988-998. PubMed ID: 29132681
[TBL] [Abstract][Full Text] [Related]
19. DNA Repair Gene Alterations and PARP Inhibitor Response in Patients With Metastatic Castration-Resistant Prostate Cancer.
Lu E; Thomas GV; Chen Y; Wyatt AW; Lloyd P; Youngren J; Quigley D; Bergan R; Bailey S; Beer TM; Feng FY; Small EJ; Alumkal JJ
J Natl Compr Canc Netw; 2018 Aug; 16(8):933-937. PubMed ID: 30099369
[No Abstract] [Full Text] [Related]
20. BRCA1 Mutation: A Predictive Marker for Radiation Therapy?
Kan C; Zhang J
Int J Radiat Oncol Biol Phys; 2015 Oct; 93(2):281-93. PubMed ID: 26383678
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]